- Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial | NEJM nejm.org
- A new weight-loss drug dubbed the ‘triple G’ could be stronger than Ozempic, Wegovy, and Mounjaro — and as powerful as bariatric surgery Yahoo Life
- Eli Lilly’s Experimental Weight-Loss Shot Gives Company’s Strongest Results Yet Bloomberg
- Lilly links oral drug to 15% weight loss, setting bar for Pfizer FierceBiotech
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial The Lancet
- View Full Coverage on Google News
Read More: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial | NEJM